960305-54-8

Usage

Uses

Used in Pharmaceutical Industry:
2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate is used as a potential active pharmaceutical ingredient for the development of new drugs due to its demonstrated pharmacological properties. Its anti-inflammatory, analgesic, and antioxidant effects make it a candidate for treating various conditions that could benefit from these therapeutic actions.
Used in Drug Development Research:
In the field of drug development, 2-tert-Butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate serves as a subject of ongoing research to further elucidate its pharmacokinetic and pharmacodynamic properties. Understanding these aspects is crucial for optimizing its potential use in medical treatments and for improving its efficacy and safety profile.

Upstream product

• 149353-95-7 2-[(tert-butoxy)carbonyl]-1 ,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 
• 75-52-5 nitromethane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 220247-69-8 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate hydrochloride 
• 67-56-1 methanol 
• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 201230-82-2 carbon monoxide 

Downstream Products

• 220247-50-7 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate 
• 149353-95-7 2-[(tert-butoxy)carbonyl]-1 ,2,3,4-tetrahydroisoquinoline-7-carboxylic acid 
• 1436422-07-9 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-(2-(methylsulfonyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436426-34-4 tert-butyl 7-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1436422-17-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436422-20-6 2-butyl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 
• 1436423-83-4 2-butyryl-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide 

Relevant academic research and scientific papers

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS

Novel thiazole- and isoquinoline- containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-specturm viral infections are also presented. These compounds have shown inhibitio of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds

Compounds of a certain formula I wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors.